PNPLA3 and metabolic dysfunction-associated steatohepatitis: Though the evidence is currently sparse, it has been suggested that genetic factors also determine the response to NASH therapy e.g., decreased effect of polyunsaturated fatty acids (PUFA) or fish oil in patients with fatty liver with PNPLA3 variant [57].